Last updated: 2026-09-05 17:13:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Galectin Therapeutics Inc. (GALT) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $4.61, with a market capitalization of $451.81M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.03 to $7.13. This page covers its latest market performance, valuation, price trends and company information.
$451.81M | |
$4.33 | |
$19.11 | |
$0.49 | |
$4.35 | |
452.04K | |
-- | |
-- | |
$7.13 | |
$2.03 | |
-- | |
-- |
Galectin Therapeutics Inc. (GALT) last closed at $4.35 as of 2026-09-04 23:59:00, unchanged from the previous close of $4.35.
During the latest regular trading session, GALT traded between $0.49 and $19.11, with a volume of 452.04K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Galectin Therapeutics Inc. (GALT) moved from $4.02 to $4.61, representing a gain of 14.60% ($0.59).
The stock traded between $4.30 and $4.72 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 357.73 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 50.6%
GALT is currently trading at $4.61, placing it 50.6% of the way from its 52-week low of $2.03 to its 52-week high of $7.13. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 9 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Galectin Therapeutics Inc. (GALT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.